Hinge Health, Inc. Q2 2026 Earnings Call Summary
Hinge Health reported Q2 2026 revenue up 53% year over year, citing higher yield from targeted enrollment and referrals. Operating margin rose 1,000 bps to 29%. Full-year 2026 revenue guidance increased to $856 million-$860 million. Hinge plans to expand beyond MSK via a $105 million acquisition of Cylinder Health, expected to add $7 million-$8 million in 2026 revenue and lift margins over 1-2 years.
How this was made
The 30-second read
Why it matters
Traders can update models using the raised FY revenue range, margin expansion to 29%, and quantified acquisition contribution ($7M-$8M for remainder of 2026), while monitoring integration timing (complete by summer 2027) and dilution from preferred conversions.
Market read
The combination of raised guidance, strong operating leverage, and a sizable buyback authorization is likely to be the dominant near-term driver, with execution risk around Cylinder integration and dilution from preferred conversions.
What to watch
Diluted share count is expected to rise to 85M-87M by year-end from preferred conversions, which can partially offset buyback support; tariff refund also boosted gross margin by ~100 bps, potentially distorting underlying profitability.
Background
The piece summarizes Hinge Health’s Q2 2026 earnings call, focusing on platform expansion, the $105M Cylinder Health acquisition, margin/yield drivers, and updated FY guidance.
Ticker impact
Hinge Health raised full-year 2026 revenue guidance to $856M-$860M and authorized a $300M share repurchase after Q2 results and margin expansion.
Likely positive bias for the next few sessions as traders reprice FY growth and margin trajectory, tempered by integration and dilution concerns.
The article provides multiple decision-relevant datapoints: raised revenue range, 1,000 bps margin expansion to 29%, and a new $300M repurchase authorization, alongside a $105M acquisition expected to close later this quarter.
Market effects
Reinforces the digital MSK-to-multi-indication care automation narrative and highlights AI-driven yield and margin leverage in value-based care platforms.
No explicit regional market effects described.
No explicit global market effects described.
Counterpoint
Cylinder Health is currently loss-making and integration costs could delay margin normalization, making the long-term 35%+ target optimistic.
Key entities
- companyHinge Health, Inc.
Digital care platform provider reporting Q2 2026 results, raised FY 2026 revenue guidance, and announcing a $105M acquisition of Cylinder Health plus a $300M share repurchase authorization.
- acquired_companyCylinder Health
Acquisition target for $105M, positioned to accelerate entry into GI health and projected to contribute $7M-$8M revenue for the remainder of 2026.
